Eli Lilly Bags $275 Million Deal to Supply Additional Doses Of COVID-19 Antibody Drug in US
© MT Newswires 2022
All news about ELI LILLY AND COMPANY |
|
|
|
Analyst Recommendations on ELI LILLY AND COMPANY |
|
|
| |
|
Sales 2022 |
28 860 M
-
-
|
Net income 2022 |
6 375 M
-
-
|
Net Debt 2022 |
9 953 M
-
-
|
P/E ratio 2022 |
44,7x |
Yield 2022 |
1,23% |
|
Capitalization |
301 B
301 B
-
|
EV / Sales 2022 |
10,8x |
EV / Sales 2023 |
10,2x |
Nbr of Employees |
35 000 |
Free-Float |
99,7% |
|
Chart ELI LILLY AND COMPANY |
|
Duration :
Period :
|
 |
|
Technical analysis trends ELI LILLY AND COMPANY
| Short Term | Mid-Term | Long Term | Trends | Neutral | Bullish | Bullish |
Income Statement Evolution
|
Mean consensus |
OUTPERFORM |
Number of Analysts |
23 |
Last Close Price |
316,82 $ |
Average target price |
327,10 $ |
Spread / Average Target |
3,24% |
|